Dr. Korenman was a Westinghouse (now Regeneron) Science Talent Search Finalist. He Graduated from Princeton, Summa Cum Laude and attended medical school at Columbia, P&S. He completed his clinical training in Internal Medicine at Bellevue and Memorial Hospitals in New York.
He became a Clinical Associate and Senior Investigator in the Endocrinology Branch of the National Cancer Institute (now CHD). He joined the UCLA faculty in 1966 at Harbor General Hospital as Assistant and then Associate Professor. He moved to the University of Iowa in 1970 where he was Professor of Medicine and Biochemistry only to return to UCLA as Professor of Medicine and Chair of the Department of Medicine at the newly formed San Fernando Valley Program and Chief of Medicine at the Sepulveda VA Medical Center. During that time he also developed and directed the UCLA Medical Scientist Training Program and became Associate Dean. He moved to the Center for the Health Sciences as Associate Dean for Educational Development and then became Chief of Endocrinology and Metabolism of the program at the Center for the Health Sciences. During the course of his career he has been active in the Endocrine Society as a member of the Council, Founding chair of the Ethics Committee and recipient of the Distinguished Teaching Award.
At present he is Associate Dean for Ethics with a special interest in research ethics and directs the Ethics consultation service of the CTSI. He continues an active general endocrine practice but focuses on Reproductive Endocrinology from the viewpoint of internal medicine. That includes in males, symptomatic reduced hormone secretion, gynecomastia, infertility and erectile dysfunction and in the female PCOS, abnormal or absent menstrual cycles, menopause, perimenopause, hirsutism, alopecia, and their consequences. He also has a substantial practice involving the endocrine aspects of gender transition.
At present, Dr. Korenman’s active research involves transgender patients. The goal is to learn in more detail what these patients actually want in terms of phenotypic and emotional changes and to design personalized therapeutic (hormonal) approaches with measurable results. Considering the great variability found when addressing goals with patients, therapeutic initiatives are expected to expand.